http://www.ptca.org/news/2011/0403_PARTNER.html
Catheter-Based Aortic Valve Replacement Equal to Surgery
The much-anticipated findings from the PARTNER trial, comparing the standard surgical procedure of aortic valve replacement (AVR) to the newer and, as of yet, unapproved in the U.S. transcatheter-based version (TAVR), were presented today at the American College of Cardiology's 60th Annual Scientific Session in New Orleans -- and the two methods of treatment were judged virtually equivalent at one year.
The study reported results from "Cohort A" of the PARTNER trial which randomized patients who were at high risk for surgery either to the tried-and-true surgical approach or to treatment with the SAPIEN valve, manufactured by Edwards Lifesciences (NYSE: EW ), which is delivered via catheter, usually via the femoral artery.
For further details:
Catheter-Based Aortic Valve Replacement Equal to Surgery
The much-anticipated findings from the PARTNER trial, comparing the standard surgical procedure of aortic valve replacement (AVR) to the newer and, as of yet, unapproved in the U.S. transcatheter-based version (TAVR), were presented today at the American College of Cardiology's 60th Annual Scientific Session in New Orleans -- and the two methods of treatment were judged virtually equivalent at one year.
The study reported results from "Cohort A" of the PARTNER trial which randomized patients who were at high risk for surgery either to the tried-and-true surgical approach or to treatment with the SAPIEN valve, manufactured by Edwards Lifesciences (NYSE: EW ), which is delivered via catheter, usually via the femoral artery.
For further details:
No comments:
Post a Comment